- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
TB Protein May Aid Drug Delivery
19 May 1998 7:30 pm
ATLANTA--A cell-piercing protein from the bacterium that causes tuberculosis (TB) could serve as a delivery system for future medicines. At the American Society for Microbiology's annual meeting here researchers reported yesterday that they had identified a short protein sequence that is key to the TB bacterium's ability to invade cells. Down the road, the protein may provide researchers with a powerful new tool to infuse cells with protein-based drugs and healthy genes for gene therapy.
Cells are normally very selective about what types of compounds they allow inside. While small molecules such as salt or carbohydrates readily pass through their membranes, larger molecules, such as proteins and nucleic acids, are blocked. Nevertheless, the TB bacterium and other cellular invaders manage to breach this barrier and force their way inside. Now researchers at the University of California at Berkeley have identified a TB protein called Mycobacterium Cell Entry Protein (MCEP), which pierces cells like a spear and allows TB to wedge through the membrane. The group, led by Lee Riley, then isolated what seems to be the spear's hardened point: A peptide containing just 22 of MCEP's 400 amino acids, which manages to worm its way into cells with nearly the same efficiency as the complete protein.
Next, the researchers tested whether their peptide--dubbed INV3--could shuttle other cargoes into cells. When they linked INV3 to a harmless, noninvasive strain of E. coli, they found that the bacteria were able to enter epithelial cells. They also linked it to b-galactosidase, a commonly used enzymatic marker that generates an intense blue color when it metabolizes the sugar galactose. When the enzyme was linked to the peptide, it could penetrate epithelial cells and turn them blue.
In an ironic twist, the new molecular shuttle may even prove useful in fighting TB, says Riley. The antibiotic amoxycillin is highly effective at killing TB in culture, but it doesn't work as well in the body, where the bacterium hides out inside cells. But amoxycillin microcapsules coated with INV3 or MCEP might penetrate infected cells, killing TB in its hiding place.
"This development sounds very interesting," says John Collier, a biomedical engineer at the Massachusetts Institute of Technology. "Breaching cell membranes with drugs has been an unsolved problem for 30 years. The question is can you get to the targeted cell without damaging other cells."